SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-025490
Filing Date
2022-09-09
Accepted
2022-09-09 16:15:37
Documents
56
Period of Report
2022-07-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 976881
2 ex10-1.htm EX-10.1 26314
3 ex31-1.htm EX-31.1 16365
4 ex31-2.htm EX-31.2 17199
5 ex32-1.htm EX-32.1 6429
6 ex32-2.htm EX-32.2 7589
  Complete submission text file 0001493152-22-025490.txt   4505664

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE anix-20220731.xsd EX-101.SCH 29249
8 XBRL CALCULATION FILE anix-20220731_cal.xml EX-101.CAL 41869
9 XBRL DEFINITION FILE anix-20220731_def.xml EX-101.DEF 127385
10 XBRL LABEL FILE anix-20220731_lab.xml EX-101.LAB 258770
11 XBRL PRESENTATION FILE anix-20220731_pre.xml EX-101.PRE 195884
50 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 796571
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 221236366
SIC: 2834 Pharmaceutical Preparations